Eli Lilly has entered a definitive agreement to acquire obesity drugmaker Versanis for $1.93 billion — a move that will boost Eli Lilly’s weight loss drug treatment portfolio. Versanis is a privately-held biopharmaceutical company and currently has one experimental drug for obesity called bimagrumab, which is being studied in a phase 2 trial. It is […]